Table 2.
Parameter | AALF | NAALF |
---|---|---|
Number of patients | 23 | 9 |
Number of patients transplanted/died | 8/23 | 4/9 |
MERTK monocyte expression (%) | 51.50** [40.75–73.75] |
35.95 [31.45–52.25] |
WCC (×109/L) |
9.57 [6.34–15.96] |
11.4 [8.0–18.4] |
Monocytes (×109/L) |
0.21** [0.14–0.36] |
0.54 [0.31–0.98] |
Creatinine (μmol/L) |
148 [76.5–237.5] |
193 [93–362] |
INR | 6.4** [3.0–8.4] |
2.7 [1.4–4.6] |
Bilirubin (μmol/L) |
74 [48–96] |
172 [42.5–587] |
Lactate (mmol/L) |
3.0 [2.2–6.8] |
2.7 [1.8–4.0] |
AST (IU/mL) |
5172* [1500–7436] |
2088 [432–6176] |
Encephalopathy | 2* [1–3] |
1 [1–2] |
SIRS score | 2 [1–3] |
2 [0–3] |
APACHE II | 19 [14–25.5] |
20 [11–27] |
SOFA | 12 [10–15.5] |
13 [10–16.5] |
MELD | 40 [33–40] |
38 [24–40] |
*p<0.05 and **p<0.01, compared with NAALF group.
APACHE II, Acute Physiology and Chronic Health Evaluation II score; AST, aspartate aminotransferase; INR, international normalised ratio; MELD, Model for End Stage Liver Disease; SIRS, systemic inflammatory response syndrome; SOFA, Sequential Organ Failure Assessment score; WCC, white (leucocyte) cell count.